AstraZeneca: FDA approves Calquence tablets

(CercleFinance.com) - AstraZeneca announced on Friday that the FDA has approved Calquence tablets for the same indications as the capsule version of the drug.


The biopharmaceutical company said the decision follows clinical trials that showed Calquence tablets and capsules had the same efficacy and safety profile.

The tablet formulation simply has the advantage that it can be taken with agents that reduce the amount of stomach acid, the company said in a statement.

Calquence is currently approved in the US for several indications, including chronic lymphocytic leukaemia, the most common in Western adults.

The drug is also approved for the treatment of mantle cell lymphoma, an aggressive non-Hodgkin's lymphoma with a poor prognosis.



Copyright (c) 2022 CercleFinance.com. All rights reserved.